Congenital HI is a rare genetic condition that results in persistent hypoglycemia due to the overproduction of insulin. Ersodetug, a fully human monoclonal antibody, binds allosterically to insulin ...
Study did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared ...
Rezolute (RZLT) announced topline results from its Phase 3 sunRIZE study evaluating ersodetug in patients with congenital hyperinsulinism, or HI.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback